Cargando…

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

BACKGROUND: HER2 mutation is found in 1%–2% of lung cancer patients. Studies comparing chemotherapy to HER2‐TKIs are limited. This study aimed to investigate the molecular and clinical patterns of HER2 mutations in advanced non‐small cell lung cancer (NSCLC), and compare the different outcomes betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Fei, Yang, Guangjian, Xu, Haiyan, Yang, Lu, Qiu, Weini, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049517/ https://www.ncbi.nlm.nih.gov/pubmed/31975535 http://dx.doi.org/10.1111/1759-7714.13317

Ejemplares similares

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
por: Yang, Yaning, et al.
Publicado: (2023)

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
por: Xu, Haiyan, et al.
Publicado: (2021)

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
por: Yang, Guangjian, et al.
Publicado: (2022)

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
por: Xu, Haiyan, et al.
Publicado: (2019)

A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients
por: Xu, Fei, et al.
Publicado: (2022)

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance
por: Xu, Haiyan, et al.
Publicado: (2019)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
por: Xu, Haiyan, et al.
Publicado: (2022)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
por: Tu, Hai‐Yan, et al.
Publicado: (2023)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
por: Yang, Guangjian, et al.
Publicado: (2022)

The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
por: Zhang, Shuyang, et al.
Publicado: (2023)

Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery
por: Yang, Lu, et al.
Publicado: (2020)

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
por: Mao, Shiqi, et al.
Publicado: (2023)

Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer
por: Xu, Haiyan, et al.
Publicado: (2018)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
por: Yang, Guangjian, et al.
Publicado: (2019)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Huang, Lan, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

HER2 mutations in Chinese patients with non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2016)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
por: Mu, Yuxin, et al.
Publicado: (2023)

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
por: Bhateja, Priyanka, et al.
Publicado: (2019)

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
por: Wei, Xue‐Wu, et al.
Publicado: (2020)

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
por: Diao, Wei-Ying, et al.
Publicado: (2021)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020)

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
por: Shan, Ling, et al.
Publicado: (2015)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Characteristics of Familial Lung Cancer in Yunnan-Guizhou Plateau of China
por: Ding, Xiaojie, et al.
Publicado: (2018)

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation
por: Yang, Shifeng, et al.
Publicado: (2018)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies
por: Zhou, Jiebai, et al.
Publicado: (2020)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
por: Jänne, Pasi A., et al.
Publicado: (2022)

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
por: Yang, Shuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hkmir6ol979ebignf3dbstmtrd